GSK rebuffs Pfizer takeover bid

anonymous · Nov 7, 2015 at 9:21 AM

Sounds like a wanna-be CEO.......if you are employed with us which I doubt, just stick to your job, keep your eyes down and be quiet. If not, they may get you.

anonymous · Nov 7, 2015 at 1:21 PM

They pulled the tablecloth right out from under the "great" parched grannietagine!

anonymous · Nov 7, 2015 at 4:33 PM

anonymous said: ↑

We seem to be pinning our hopes on Nucala and shingles vaccine in the near term coupled with sales improvement on Breo, Anoro, Incruse, and Tanzeum. I see many problems with this strategy.

1- Nucala is for very severe patients and is a buy and bill which is a niche. Pulmonoligists and allergists broadly speaking will not take on that risk of stocking a product and hoping to get reimbursed down the line. Same issues led to pharmacies taking on vaccines. If we can't be successful launching Anoro etc. how will we convince HCPs to use what is likely an expensive biological in office. Insurance coverage will likely be fragmented as I am sure not all payers will see the value. This is headed no where fast.

2- shingles vaccine is two doses and contains an adjuvant like cervarix did. Wall Street analysts were all over this and seemed concerned about this in their questioning. At R&D day they said Merck's product has only vaccinated 25% of eligible population with their one dose vaccine after 10 years on market. Why do we think we are going to do any better with a 2 dose vaccine which will have negative adjuvant and safety concerns and likely be more expensive. GSK vaccines has had multiple failures and delays in the past with vaccines. We are always late coming to market. This is Cervarix all over again but will be an even worse disaster. There is nothing else in the vaccine pipeline besides early phase gambles.

3- Breo, Anoro, incruse are failures compared to expectations. No way these products will make up even half of advair sales (4x4!!!!) This is a very crowded class and payers are pinning everyone down for large rebates for coverage. We have GSK reps selling breo and incruse, another group selling anoro, and inventiv people selling it as well. Customers must love that confusion. We are also giving it away for free for two years. This is simply not sustainable.

4- Tanzeum is in another crowded class where we compete with companies who are diabetes leaders. A leader in diabetes, we are not. I have friends on this team who tell me they are lucky to get 5 scripts a week. The nation goal of 100M in sales is a rounding error. We are also giving it away for free for 2 years and have a huge expensive sales force. This is also not sustainable.

I imagine the R&D day was a bit of a gamble designed to prop up the stock and potentially bid Pfizer up to come back to us in the game of hard to get. This failed miserably and they seem to have moved on. It seems Wall Street wasn't buying it either. See Forbes article "GSK's Vision needs more Vision" for post R&D summary. Pfizer probably approached GSK and said they are willing to come in and do a friendly deal and stop the bleeding for a fair price. GSK got greedy and probably felt they could get more hence the unusual dog and pony show put on in NYC, home to Pfizer. Now the emperor has no clothes but Witty will find a way to hang his hat on something ( for now the promise of 20 new products by 2020..... Get it, our talking point will be 20 x 20!!!!) in order to kick the can down the road a bit the same way they used the Novartis deal to buy them a year. Trouble is ahead my friends. Buckle up. Good luck to all.
Click to expand...

Outstanding post. Being on the pharma side I did not appreciate the X 2 shingles vaccine nor potential safety issues with the adjuvants. The RSV vaccine outlined in the presentation is very high risk

I agree buckle up and good luck to all

anonymous · Nov 7, 2015 at 5:48 PM

Great summary. Wannabe CEO? My hope is that this person is employed by GSK. The company needs more realistic people making decisions rather then empty talking heads. That article by Max Nisen about the RandD day was a scathing review of the future of the company. Google it. Stinks to be a shareholder.

anonymous · Nov 7, 2015 at 10:46 PM

anonymous said: ↑

Great summary. Wannabe CEO? My hope is that this person is employed by GSK. The company needs more realistic people making decisions rather then empty talking heads. That article by Max Nisen about the RandD day was a scathing review of the future of the company. Google it. Stinks to be a shareholder.
Click to expand...

Agree Max's article was spot on. His father was the former SVP of R&D Innovation at GSK so Max knows what he is writing about.

anonymous · Nov 8, 2015 at 6:06 AM

Thank you, post #39! It is to occasionally read a post from someone like you that I am still willing to wade through all of the other crap here on the gsk CP site. Much appreciated.

anonymous · Nov 8, 2015 at 6:24 PM

anonymous said: ↑

Thank you, post #39! It is to occasionally read a post from someone like you that I am still willing to wade through all of the other crap here on the gsk CP site. Much appreciated.
Click to expand...

It is sickening to watch you try and promote your post over and over again. Talk about insecurity.

anonymous · Nov 8, 2015 at 8:23 PM

anonymous said: ↑

It is sickening to watch you try and promote your post over and over again. Talk about insecurity.
Click to expand...

Yes, nauseating. He/she probably had their mother, father, bubbie, all post about what a great post this was when nothing in it was even new.

anonymous · Nov 10, 2015 at 7:03 AM

anonymous said: ↑

Yes, nauseating. He/she probably had their mother, father, bubbie, all post about what a great post this was when nothing in it was even new.
Click to expand...

Yes his Bubbie was working overtime posting messages about what a genius he is

anonymous · Nov 10, 2015 at 7:12 AM

anonymous said: ↑

Yes his Bubbie was working overtime posting messages about what a genius he is
Click to expand...

And did she mention how funny he is? That Bubbie is really nice isn't she ?

anonymous · Nov 10, 2015 at 8:22 AM

anonymous said: ↑

We seem to be pinning our hopes on Nucala and shingles vaccine in the near term coupled with sales improvement on Breo, Anoro, Incruse, and Tanzeum. I see many problems with this strategy.

1- Nucala is for very severe patients and is a buy and bill which is a niche. Pulmonoligists and allergists broadly speaking will not take on that risk of stocking a product and hoping to get reimbursed down the line. Same issues led to pharmacies taking on vaccines. If we can't be successful launching Anoro etc. how will we convince HCPs to use what is likely an expensive biological in office. Insurance coverage will likely be fragmented as I am sure not all payers will see the value. This is headed no where fast.

2- shingles vaccine is two doses and contains an adjuvant like cervarix did. Wall Street analysts were all over this and seemed concerned about this in their questioning. At R&D day they said Merck's product has only vaccinated 25% of eligible population with their one dose vaccine after 10 years on market. Why do we think we are going to do any better with a 2 dose vaccine which will have negative adjuvant and safety concerns and likely be more expensive. GSK vaccines has had multiple failures and delays in the past with vaccines. We are always late coming to market. This is Cervarix all over again but will be an even worse disaster. There is nothing else in the vaccine pipeline besides early phase gambles.

3- Breo, Anoro, incruse are failures compared to expectations. No way these products will make up even half of advair sales (4x4!!!!) This is a very crowded class and payers are pinning everyone down for large rebates for coverage. We have GSK reps selling breo and incruse, another group selling anoro, and inventiv people selling it as well. Customers must love that confusion. We are also giving it away for free for two years. This is simply not sustainable.

4- Tanzeum is in another crowded class where we compete with companies who are diabetes leaders. A leader in diabetes, we are not. I have friends on this team who tell me they are lucky to get 5 scripts a week. The nation goal of 100M in sales is a rounding error. We are also giving it away for free for 2 years and have a huge expensive sales force. This is also not sustainable.

I imagine the R&D day was a bit of a gamble designed to prop up the stock and potentially bid Pfizer up to come back to us in the game of hard to get. This failed miserably and they seem to have moved on. It seems Wall Street wasn't buying it either. See Forbes article "GSK's Vision needs more Vision" for post R&D summary. Pfizer probably approached GSK and said they are willing to come in and do a friendly deal and stop the bleeding for a fair price. GSK got greedy and probably felt they could get more hence the unusual dog and pony show put on in NYC, home to Pfizer. Now the emperor has no clothes but Witty will find a way to hang his hat on something ( for now the promise of 20 new products by 2020..... Get it, our talking point will be 20 x 20!!!!) in order to kick the can down the road a bit the same way they used the Novartis deal to buy them a year. Trouble is ahead my friends. Buckle up. Good luck to all.
Click to expand...

Excellent post. Spot on. Good luck to all

anonymous · Nov 10, 2015 at 8:25 AM

anonymous said: ↑

And did she mention how funny he is? That Bubbie is really nice isn't she ?
Click to expand...

Boing!

anonymous · Nov 10, 2015 at 11:15 PM

GSK was idiotic to reject a buyout from Pfizer.

anonymous · Nov 11, 2015 at 6:26 AM

anonymous said: ↑

GSK was idiotic to reject a buyout from Pfizer.
Click to expand...

Don't assume this is a done deal

anonymous · Nov 11, 2015 at 6:48 AM

anonymous said: ↑

Excellent post. Spot on. Good luck to all
Click to expand...

Wow, we were all worried there for a minute that you wouldn't like your own post. Glad to see that you clarified that.

anonymous · Nov 11, 2015 at 11:01 AM

Why would anyone want to be bought by Pfizer ?

anonymous · Nov 23, 2015 at 7:49 PM

anonymous said: ↑

Why would anyone want to be bought by Pfizer ?
Click to expand...

Well Allergan thinks there are $160 billion reasons why

anonymous · Nov 24, 2015 at 10:36 AM

.......and so , you have sold your soul !

anonymous · Nov 24, 2015 at 5:03 PM

Post #39

Brilliant!! Simply brilliant.

anonymous · Nov 25, 2015 at 2:55 PM

anonymous said: ↑

Post #39

Brilliant!! Simply brilliant.
Click to expand...

Another post from the Bubbie of the idiot that posted #39. OK we get it, you like to post repeat posts saying how great your posts are.

GSK rebuffs Pfizer takeover bid

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

Useful Searches

GSK rebuffs Pfizer takeover bid

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest

anonymous Guest